In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson's Strategy for Beating the Big Boys

Executive Summary

Watson's launch of incontinence drug Oxytrol illustrates the opportunities and challenges specialty pharma companies face when they try to move into primary care markets dominated by Big Pharma. Watson's added a whole set of Big Pharma-experienced managers and is betting that their expertise can guide it through the intimidating process of selecting and launching products. Even so, launching a product into primary care markets requires a commitment that stresses resources and changes the corporate culture.

You may also be interested in...



Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?

Watson is in discussions with potential primary care partners for its newly approved benign prostatic hyperplasia therapy Rapaflo (silodosin)

Teasing Out Next-Generation Diabetes Drugs

Many start-ups are developing diabetes drugs based on known targets which could attract Big Pharma partners and get to the clinic quickly, while a few invest in novel compounds that are either riskier or address the field's smaller subsets. Among the former are Phenomix, Plexxikon, CareX and Prosidion; among the latter are DiaKine, and DiaMedica. In all cases, these companies are looking to partner with Big Pharma, which is aggressively pursuing small-molecule drugs for diabetes.

Endo: Accessing Primary Care through Specialist Marketing

Endo believes its specialist approach to pain management is key to eventually winning over a respectable market share in primary care, given that it can successfully differentiate Frova, the sixth-in-class migraine treatment it licensed from Vernalis in July 2004. Skeptics point to the failure of previous owners of Frova to gain the drug any primary care notice since its launch in mid-2002. Endo chairman and CEO Carol Ammon contends that the company can inexpensively exploit the unique characteristics of the drug in the medical community and succeed where others have failed through a singular focus on specialist medicine that she claims as its bailiwick.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel